Print

ANRS VAC 02

Phase I trial of gp160 protein subunit plus gp120 protein subunit MN gp120 (subtype B) plus gp41 protein subunit LAI gp41 (subtype B) with the boost of peptide vaccine from V3 domain of the envelope protein.

Trial Details:

I Completed
French National Agency for Research on AIDS and viral hepatitis (ANRS) Aventis-Pasteur July 01, 1992
rgp 160 + peptide V3 ANRS VAC 02 Env gp160 (gp120 MN, gp41 LAI); V3 MN
rgp 160 + peptide V3 ANRS VAC 02 Protein
France 25
http://www.anrs.fr/